Barcelona, Spain, December, 16 2020. ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the lives of more than 9 million people globally each year, metastatic cancers are often unresponsive to existing cancer treatments, leaving a large unmet need. In order to tackle this important health problem, the newly established consortium – named LIPOLOGIC – will combine industry know-how in complementary areas of drug development: from target discovery, across molecule formatting and manufacturing, to lead selection and characterization.

See more details in the press release